Sotorasib and panitumumab named new standard of care for metastatic colorectal cancer

The combination of sotorasib and panitumumab outperformed researchers’ treatment of choice in a phase 3 trial in chemotherapy-resistant patients. classG12C– Mutant metastatic colorectal cancer (CRC). Researchers tested the combination with two different doses of sotorasib and found that both doses improved progression-free survival (PFS). However, outcomes were better with higher doses of sotorasib. “The combination […]